Familial Early-Onset Alzheimer's Caused by Novel Genetic Variant and APP Duplication: A Cross-Sectional Study | Bentham Science
Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Familial Early-Onset Alzheimer's Caused by Novel Genetic Variant and APP Duplication: A Cross-Sectional Study

Author(s): Limor Kalfon, Rotem Paz, Hadas Raveh-Barak, Areef Salama, Nadra Samra, Alexander Kaplun, Natalia Chasnyk, Nehama Cohen Kfir, Nissreen Kinaani Mousa, Efrat Shuster Biton, Mary Tanus, Judith Aharon-Peretz and Tzipora C. Falik Zaccai*

Volume 19, Issue 10, 2022

Published on: 07 November, 2022

Page: [694 - 707] Pages: 14

DOI: 10.2174/1567205020666221020095257

Price: $65

Open Access Journals Promotions 2
Abstract

Background: The clinical characteristics of symptomatic and asymptomatic carriers of early- onset autosomal dominant Alzheimer’s (EOADAD) due to a yet-undescribed chromosomal rearrangement may add to the available body of knowledge about Alzheimer’s disease and may enlighten novel and modifier genes. We report the clinical and genetic characteristics of asymptomatic and symptomatic individuals carrying a novel APP duplication rearrangement.

Methods: Individuals belonging to a seven-generation pedigree with familial cognitive decline or intracerebral hemorrhages were recruited. Participants underwent medical, neurological, and neuropsychological evaluations. The genetic analysis included chromosomal microarray, Karyotype, fluorescence in situ hybridization, and whole genome sequencing.

Results: Of 68 individuals, six females presented with dementia, and four males presented with intracerebral hemorrhage. Of these, nine were found to carry Chromosome 21 copy number gain (chr21:27,224,097-27,871,284, GRCh37/hg19) including the APP locus (APP-dup). In seven, Chromosome 5 copy number gain (Chr5: 24,786,234-29,446,070, GRCh37/hg19) (Chr5-CNG) cosegregated with the APP-dup. Both duplications co-localized to chromosome 18q21.1 and segregated in 25 pre-symptomatic carriers. Compared to non-carriers, asymptomatic carriers manifested cognitive decline in their mid-thirties. A third of the affected individuals carried a diagnosis of a dis-immune condition.

Conclusion: APP extra dosage, even in isolation and when located outside chromosome 21, is pathogenic. The clinical presentation of APP duplication varies and may be gender specific, i.e., ICH in males and cognitive-behavioral deterioration in females. The association with immune disorders is presently unclear but may prove relevant. The implication of Chr5-CNG co-segregation and the surrounding chromosome 18 genetic sequence needs further clarification.

Keywords: Early-onset Alzheimer's disease, copy number variation, APP duplication, chromosomal aberrations, consanguineous family, intra-cerebral hemorrhages.

« Previous Next »
[1]
Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65(3): 664-70.
[http://dx.doi.org/10.1086/302553] [PMID: 10441572]
[2]
Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995; 375(6534): 754-60.
[http://dx.doi.org/10.1038/375754a0] [PMID: 7596406]
[3]
Chartier-Harlin MC, Crawford F, Houlden H, et al. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 1991; 353(6347): 844-6.
[http://dx.doi.org/10.1038/353844a0] [PMID: 1944558]
[4]
Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer’s disease with cerebral amyloid angiopathy. Nat Genet 2006; 38(1): 24-6.
[http://dx.doi.org/10.1038/ng1718] [PMID: 16369530]
[5]
Aguirre-Acevedo DC, Jaimes-Barragán F, Henao E, et al. Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer’s disease affected by E280A mutation on presenilin-1 gene. Int Psychogeriatr 2016; 28(3): 503-10.
[http://dx.doi.org/10.1017/S1041610215001660] [PMID: 26478578]
[6]
Jia L, Fu Y, Shen L, et al. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer’s disease. Alzheimers Dement 2020; 16(1): 178-91.
[http://dx.doi.org/10.1002/alz.12005] [PMID: 31914229]
[7]
Qin Q, Yin Y, Wang Y, Lu Y, Tang Y, Jia J. Gene mutations associated with early onset familial Alzheimer’s disease in China: An overview and current status. Mol Genet Genomic Med 2020; 8(10): e1443.
[http://dx.doi.org/10.1002/mgg3.1443] [PMID: 32767553]
[8]
Mao C, Li J, Dong L, et al. Clinical phenotype and mutation spectrum of Alzheimer’s disease with causative genetic mutation in a Chinese cohort. Curr Alzheimer Res 2021; 18(3): 265-72.
[http://dx.doi.org/10.2174/1567205018666210608120339] [PMID: 34102969]
[9]
Prokopenko D, Lee S, Hecker J, et al. Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimer’s disease-associated genes: DTNB and DLG2. Mol Psychiatry 2022; 27(4): 1963-9.
[http://dx.doi.org/10.1038/s41380-022-01475-0] [PMID: 35246634]
[10]
Shigemizu D, Asanomi Y, Akiyama S, Mitsumori R, Niida S, Ozaki K. Whole-genome sequencing reveals novel ethnicity-specific rare variants associated with Alzheimer’s disease. Mol Psychiatry 2022; 27(5): 2554-62.
[http://dx.doi.org/10.1038/s41380-022-01483-0] [PMID: 35264725]
[11]
Meng X, Wei Q, Meng L, Liu J, Wu Y, Liu W. Feature fusion and detection in Alzheimer’s disease using a novel genetic multi-kernel SVM based on MRI imaging and gene data. Genes (Basel) 2022; 13(5): 837.
[http://dx.doi.org/10.3390/genes13050837]
[12]
Giau V, Wu S, Jamerlan A, An S, Kim S, Hulme J. Gut microbiota and their neuroinflammatory implications in Alzheimer’s disease. Nutrients 2018; 10(11): 1765.
[http://dx.doi.org/10.3390/nu10111765] [PMID: 30441866]
[13]
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet 2020; 396(10248): 413-46.
[14]
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002; 297(5580): 353-6.
[http://dx.doi.org/10.1126/science.1072994] [PMID: 12130773]
[15]
Shea YF, Chu LW, Chan AOK, Ha J, Li Y, Song YQ. A systematic review of familial Alzheimer’s disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences. J Formos Med Assoc 2016; 115(2): 67-75.
[http://dx.doi.org/10.1016/j.jfma.2015.08.004] [PMID: 26337232]
[16]
Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy. Brain 2006; 129(11): 2977-83.
[http://dx.doi.org/10.1093/brain/awl203] [PMID: 16921174]
[17]
Zarea A, Charbonnier C, Rovelet-Lecrux A, et al. Seizures in dominantly inherited Alzheimer’s disease. Neurology 2016; 87(9): 912-9.
[http://dx.doi.org/10.1212/WNL.0000000000003048] [PMID: 27466472]
[18]
Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer’s disease: Mechanistic insights from down syndrome. Nat Rev Neurosci 2015; 16(9): 564-74.
[http://dx.doi.org/10.1038/nrn3983] [PMID: 26243569]
[19]
Buss L, Fisher E, Hardy J, et al. Intracerebral haemorrhage in Down syndrome: Protected or predisposed? F1000 Res 2016; 5.
[http://dx.doi.org/10.12688/f1000research.7819.1]
[20]
Guyant-Marechal I, Berger E, Laquerrière A, et al. Intrafamilial diversity of phenotype associated with app duplication. Neurology 2008; 71(23): 1925-6.
[http://dx.doi.org/10.1212/01.wnl.0000339400.64213.56] [PMID: 19047566]
[21]
Mann DMA, Davidson YS, Robinson AC, et al. Patterns and severity of vascular amyloid in Alzheimer’s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer’s disease. Acta Neuropathol 2018; 136(4): 569-87.
[http://dx.doi.org/10.1007/s00401-018-1866-3] [PMID: 29770843]
[22]
Kasuga K, Shimohata T, Nishimura A, et al. Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2009; 80(9): 1050-2.
[http://dx.doi.org/10.1136/jnnp.2008.161703] [PMID: 19684239]
[23]
Bayani J, Squire JA. Fluorescence in situ Hybridization (FISH). Curr Protoc Cell Biol 2004; 28: 224.
[24]
Neerman N, Faust G, Meeks N, et al. A clinically validated whole genome pipeline for structural variant detection and analysis. BMC Genomics 2019; 20 (Suppl. 8): 545.
[http://dx.doi.org/10.1186/s12864-019-5866-z] [PMID: 31307387]
[25]
Mahley RW, Rall SC Jr, Apolipoprotein E. Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1(1): 507-37.
[http://dx.doi.org/10.1146/annurev.genom.1.1.507] [PMID: 11701639]
[26]
Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74(17): 1346-50.
[http://dx.doi.org/10.1212/WNL.0b013e3181dad605] [PMID: 20421578]
[27]
Gregoire SM, Chaudhary UJ, Brown MM, et al. The microbleed anatomical rating scale (MARS): Reliability of a tool to map brain microbleeds. Neurology 2009; 73(21): 1759-66.
[http://dx.doi.org/10.1212/WNL.0b013e3181c34a7d] [PMID: 19933977]
[28]
Hooli BV, Kovacs-Vajna ZM, Mullin K, et al. Rare autosomal copy number variations in early-onset familial Alzheimer’s disease. Mol Psychiatry 2014; 19(6): 676-81.
[http://dx.doi.org/10.1038/mp.2013.77] [PMID: 23752245]
[29]
Grangeon L, Cassinari K, Rousseau S, et al. Early-onset cerebral amyloid angiopathy and Alzheimer’s disease related to an APP locus triplication. Neurol Genet 2021; 7(5): e609.
[30]
Redies C, Hertel N, Hubner CA. Cadherins and neuropsychiatric disorders. Brain Res 2012; 1470: 130-44.
[31]
Alkan C, Coe BP, Eichler EE. Genome structural variation discovery and genotyping. Nat Rev Genet 2011; 12(5): 363-76.
[http://dx.doi.org/10.1038/nrg2958] [PMID: 21358748]
[32]
Gu W, Zhang F, Lupski JR. Mechanisms for human genomic rearrangements. PathoGenetics 2008; 1(1): 4.
[http://dx.doi.org/10.1186/1755-8417-1-4] [PMID: 19014668]
[33]
Harel T, Lupski JR. Genomic disorders 20 years on-mechanisms for clinical manifestations. Clin Genet 2018; 93(3): 439-49.
[http://dx.doi.org/10.1111/cge.13146] [PMID: 28950406]
[34]
Lee BD, Park JM, Lee YM, et al. A pilot study for discovering candidate genes of chromosome 18q21 in methamphetamine abusers: A case-control association study. Clin Psychopharmacol Neurosci 2014; 12(1): 54-64.
[http://dx.doi.org/10.9758/cpn.2014.12.1.54] [PMID: 24851122]
[35]
Mittler RS, Foell J, McCausland M, et al. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res 2004; 29(1-3): 197-208.
[http://dx.doi.org/10.1385/IR:29:1-3:197] [PMID: 15181282]

Rights & Permissions Print Cite
Article Metrics
39
3
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy